• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.

作者信息

Rowinsky Eric K

出版信息

J Clin Oncol. 2006 Jul 1;24(19):2981-4. doi: 10.1200/JCO.2006.05.9808. Epub 2006 Jun 12.

DOI:10.1200/JCO.2006.05.9808
PMID:16769983
Abstract
摘要

相似文献

1
Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.最近，我突然想到，对于法尼基转移酶抑制剂来说，这是一段多么漫长而奇特的历程。
J Clin Oncol. 2006 Jul 1;24(19):2981-4. doi: 10.1200/JCO.2006.05.9808. Epub 2006 Jun 12.
2
Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.法尼基转移酶抑制剂：临床前和临床研究结果概述
Cancer Res. 2003 Sep 15;63(18):5656-68.
3
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.用于临床癌症治疗的法尼基转移酶抑制剂的研发：聚焦血液系统恶性肿瘤
Cancer Invest. 2007 Sep;25(6):484-94. doi: 10.1080/07357900701359437.
4
Farnesyl transferase inhibitors.法尼基转移酶抑制剂
Cancer Invest. 2008 Aug;26(7):653-61. doi: 10.1080/07357900801971016.
5
Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?法尼基转移酶抑制剂：癌症化疗的合理方法？
J Med Chem. 2004 Apr 8;47(8):1869-78. doi: 10.1021/jm0305467.
6
Farnesyltransferase inhibitors.
Clin Adv Hematol Oncol. 2005 Mar;3(3):161-2.
7
[Development of farnesyltransferase inhibitor for anti-cancer drugs].[用于抗癌药物的法尼基转移酶抑制剂的研发]
Tanpakushitsu Kakusan Koso. 2007 Oct;52(13 Suppl):1713-8.
8
[Neoadjuvant systemic chemotherapy for patients with operable breast cancer].[可手术乳腺癌患者的新辅助全身化疗]
Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):161-5.
9
Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.法尼基转移酶抑制剂及其在骨髓增生异常综合征和急性髓系白血病治疗中的潜在作用。
Br J Haematol. 2008 May;141(5):576-86. doi: 10.1111/j.1365-2141.2008.07099.x. Epub 2008 Apr 10.
10
Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.法尼基转移酶及其抑制剂作为癌症治疗有希望策略的意义。
Semin Cancer Biol. 2019 Jun;56:128-134. doi: 10.1016/j.semcancer.2017.10.010. Epub 2017 Oct 31.

引用本文的文献

1
Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer.发现和评价 C6-取代的吡唑并嘧啶基双膦酸盐类人法尼基焦磷酸合酶抑制剂及其在多发性骨髓瘤、胰腺导管腺癌和结直肠癌中的抗肿瘤疗效。
J Med Chem. 2023 Dec 14;66(23):15776-15800. doi: 10.1021/acs.jmedchem.3c01271. Epub 2023 Nov 20.
2
Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer.磷脂酰丝氨酸内质网到质膜转运机制的组成部分作为胰腺癌中 KRAS 抑制的靶点。
Proc Natl Acad Sci U S A. 2021 Dec 21;118(51). doi: 10.1073/pnas.2114126118.
3
CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.CRISPR/Cas9 全基因组功能丧失筛选鉴定出参与肾细胞癌舒尼替尼耐药的可药物治疗的细胞因子。
Br J Cancer. 2020 Dec;123(12):1749-1756. doi: 10.1038/s41416-020-01087-x. Epub 2020 Sep 24.
4
Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function.靶向质膜磷脂酰丝氨酸含量抑制致癌 KRAS 功能。
Life Sci Alliance. 2019 Aug 26;2(5). doi: 10.26508/lsa.201900431. Print 2019 Oct.
5
Acylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function.酰肽水解酶是 KRAS 质膜定位和功能的新型调节因子。
J Cell Sci. 2019 Jul 31;132(15):jcs232132. doi: 10.1242/jcs.232132.
6
An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth.一种破坏 RAS 质膜定位的蒽醌衍生物可抑制癌细胞生长。
J Biol Chem. 2018 Aug 31;293(35):13696-13706. doi: 10.1074/jbc.RA118.003907. Epub 2018 Jul 3.
7
Sphingomyelin Metabolism Is a Regulator of K-Ras Function.鞘磷脂代谢是 K-Ras 功能的调节剂。
Mol Cell Biol. 2018 Jan 16;38(3). doi: 10.1128/MCB.00373-17. Print 2018 Feb 1.
8
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.KRAS/PAK1/Crk通路在非小细胞肺癌发生中的意义。
BMC Cancer. 2015 May 9;15:381. doi: 10.1186/s12885-015-1360-4.
9
Human isoprenoid synthase enzymes as therapeutic targets.人异戊烯基合成酶作为治疗靶点。
Front Chem. 2014 Jul 22;2:50. doi: 10.3389/fchem.2014.00050. eCollection 2014.
10
A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.RAS的复兴：针对KRAS突变型非小细胞肺癌的新兴靶向疗法
Clin Cancer Res. 2014 Aug 1;20(15):3921-30. doi: 10.1158/1078-0432.CCR-13-1762. Epub 2014 Jun 3.